Study: A new treatment can extend the control of regular prostate cancer

The results of a clinical trial showed that the merger of a radiological remedy addressed to a protein known as psma with sphincter radio therapy, the period that patients spend without aggravation of the disease, doubles according to what a Johnson Comprehensive Center for Cancer research team at the University of California-Los. The results, which were shown in the United States of the US Radiotherapy Association in the United States in San Francisco, indicate that patients who received double treatment lived on average 17.6 months without the development of the disease, compared to only 7.4 months for those who received radiation alone, which means the risk of relapse or the need for hormonal therapy or death by 63%. Prostate cancer is the second most common cancer among men worldwide, with about 1.4 million new cases each year, and about 375,000 deaths annually. Although the chances of survival are high at the early diagnosis, many patients suffer from the return of the disease after years of initial treatment, often in the form of limited focal points, known as the oligorrent. The results of the clinical experience are an important step that makes the treated treatment of psma closer to becoming part of standard protocols, Dr. Margaret Baker of the University of Chicago During the last decade, embodied radiotherapy has become one of the basic options to treat these cases because it enables accurate target of focused focal points, while claiming healthy tissues. But the challenge remains, as the invisible microscopic cancer cells often return to the latest image techniques, which have urged researchers to try to integrate physical therapy with targeted radiotherapy. The idea behind the new treatment is based on the target of PSMA protein, a protein that appears on the surface of the prostate cancer cells, by linking radioactive molecules to psma associated with PSMA, radiation can be directly linked to the cancer cells and destroys it from the inside, while damage to healthy cells. This approach represents an integrated model that combines diagnosis and treatment in the so -called ‘Oxusx’, which is an upward trend in modern medicine that combines the strength of exact photography with the effectiveness of the directed treatment. Is it possible to prevent prostate cancer? There is no fully confirmed way to prevent prostate cancer, but the risk can be reduced by following a healthy lifestyle, but there are methods that contribute to reducing the possibility of infection: Reduce fat consumption, especially animal fat and high -fat products. Increase fruits and vegetables daily, they are rich in nutrients that apparently reduce the risk of infection. Choose low -fat dairy products, or reduce the consuming quantities. Maintain a healthy weight – avoid obesity that can increase the risk of infection – through a balance between calories and physical activity. Exercise regularly – recommend 150 to 300 minutes per week of moderate activity, or equivalent – it is preferable to start gradually if you are not active in the past. Be refrained from smoking or getting off from it, because some evidence connects smoking and the risk of the disease or its spread. If you have high risk factors (such as a family history of an injury), consult your doctor to consider additional strategies or special follow -up exams. In the experiment, called Maans, 92 patients with regular prostate cancer were selected. The researchers randomly divided into two groups; The first was received only physical therapy, while the second two doses of the 177LU-PN2002 received radioactive middle before radiotherapy. During the succession that relied on blood tests to determine the levels of PSA antigen, a blood test used to detect prostate problems and aimed photography, it was found that the addition of the directed treatment has doubled the period free of the progress of the disease, and the need to begin hormonal therapy from 14,1 months to 24.3 months. The lead author of the study, Ammar Kishhan, said that these results represent the first random guide that the treatment for PSMA can change the course of the disease in its early stages, and that patients can give longer time before using hormonal therapy, known as its exhausting effects, such as fatigue and bone loss. While co -author Jeremy Calis believes that the combination of directed photography with radioactive treatment is a qualitative jump because it can target both visual and invisible outposts. The study was not limited to clinical results, but also monitored biological indicators who in the future could help identify patients who benefit most from the treatment. The researchers noted that patients who showed a stronger immune response to radiotherapy were better, and a genetic analysis of 20 genes related to immunity and DNA recovery predicted the degree of risk and the possibility of relapse. These results open the door for the development of personal medicine strategies, as optimal treatment is determined based on the biological footprint of each patient. Despite these promising results, 64% of patients in the group who received double treatment were later returned to them, showing that the biggest challenge remains to eliminate microscopic cancer cells. The researchers pointed out that the next phase needs longer and more comprehensive experiences, and possibly integration strategies with immune treatments to increase the effectiveness of response. The importance of the results is not only limited to the medical side, but also extends to the social and economic dimension. Hormonal treatment is long not only the health of the patient and the quality of his life, but it is a major financial burden on healthcare systems. Consequently, delaying the need for this treatment by introducing a radioactive drug that can contribute to reducing costs and maintaining the quality of patients’ lives. Independent experts praised the study with an invitation to Troy, and dr. Margaret Baker of the University of Chicago, and she did not participate in the research, believed that the results were an important step that was part of the treatment to PSMA, part of the standard protocols, but emphasized the need to undertake larger and longer experiments that include patients of different geographical and ethnic backgrounds. The future seems to be promising for this approach, as research is expected to develop more accurate particles to target PSMA, and perhaps integrate radiotherapy aimed at immune or chemical treatments to increase the efficiency of disease control. The introduction of radioactive therapy in the early stages of prostate cancer can thus become a new international standard, which changes the course of this disease, which is still a global health challenge.